3.05
price up icon0.99%   0.03
after-market Dopo l'orario di chiusura: 2.98 -0.07 -2.30%
loading
Precedente Chiudi:
$3.02
Aprire:
$2.97
Volume 24 ore:
354.90K
Relative Volume:
1.03
Capitalizzazione di mercato:
$294.90M
Reddito:
$69.56M
Utile/perdita netta:
$-240.05M
Rapporto P/E:
-1.3436
EPS:
-2.27
Flusso di cassa netto:
$-121.90M
1 W Prestazione:
+1.33%
1M Prestazione:
-7.29%
6M Prestazione:
-37.76%
1 anno Prestazione:
+281.25%
Intervallo 1D:
Value
$2.95
$3.085
Intervallo di 1 settimana:
Value
$2.81
$3.11
Portata 52W:
Value
$0.3599
$6.04

Adc Therapeutics Sa Stock (ADCT) Company Profile

Name
Nome
Adc Therapeutics Sa
Name
Telefono
41 21 653 02 00
Name
Indirizzo
BIOPOLE, EPALINGES
Name
Dipendente
274
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
ADCT's Discussions on Twitter

Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-08-10 Aggiornamento JP Morgan Underweight → Neutral
2023-04-24 Downgrade BofA Securities Neutral → Underperform
2022-12-06 Iniziato CapitalOne Overweight
2022-11-09 Downgrade BofA Securities Buy → Neutral
2022-09-21 Iniziato JP Morgan Overweight
2022-09-09 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-11-09 Iniziato Wolfe Research Outperform
2021-08-17 Ripresa Jefferies Buy
2021-08-09 Iniziato RBC Capital Mkts Outperform
2021-06-15 Iniziato Cantor Fitzgerald Overweight
2020-12-03 Iniziato Stifel Hold
2020-10-29 Iniziato H.C. Wainwright Buy
2020-06-09 Iniziato BofA/Merrill Buy
2020-06-09 Iniziato Cowen Outperform
Mostra tutto

Adc Therapeutics Sa Borsa (ADCT) Ultime notizie

pulisher
09:47 AM

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting - StockTitan

09:47 AM
pulisher
07:47 AM

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - MSN

07:47 AM
pulisher
04:27 AM

ADC Therapeutics to Present at November 2024 Investor Conferences - BioSpace

04:27 AM
pulisher
Nov 04, 2024

ADC Therapeutics to Present at November Investor Conferences - StockTitan

Nov 04, 2024
pulisher
Nov 01, 2024

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - Nasdaq

Nov 01, 2024
pulisher
Nov 01, 2024

ADC Therapeutics (ADCT) Set to Announce Earnings on Thursday - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

Cancer Antibody Drug Conjugates Market, Drugs Approval & Clinical Trials Report 2024 - GlobeNewswire Inc.

Oct 31, 2024
pulisher
Oct 31, 2024

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 - BioSpace

Oct 31, 2024
pulisher
Oct 28, 2024

Institutional investors own a significant stake of 32% in ADC Therapeutics SA (NYSE:ADCT) - Yahoo Finance

Oct 28, 2024
pulisher
Oct 21, 2024

Global Antibody-Drug Conjugate Market Set for a ~USD 26 Billion Surge by 2030 | DelveInsight - The Malaysian Reserve

Oct 21, 2024
pulisher
Oct 21, 2024

Antibody-Drug Conjugates Market to Grow at 28.4% CAGR from 2024 to 2029 - PR Newswire UK

Oct 21, 2024
pulisher
Oct 21, 2024

The Manufacturers Life Insurance Company Purchases Shares of 26,938 ADC Therapeutics SA (NYSE:ADCT) - Defense World

Oct 21, 2024
pulisher
Oct 15, 2024

ADC Therapeutics SA (NYSE:ADCT) Sees Large Growth in Short Interest - MarketBeat

Oct 15, 2024
pulisher
Oct 14, 2024

Adc Therapeutics SA’s Shares Reel: -23.19% Quarterly Revenue Decline Amid 297.81M Market Cap - The InvestChronicle

Oct 14, 2024
pulisher
Oct 14, 2024

Adc Therapeutics SA (ADCT) rating initates by Cantor Fitzgerald - Knox Daily

Oct 14, 2024
pulisher
Oct 11, 2024

ADC Therapeutics SA's (NYSE:ADCT) institutional investors lost 10% over the past week but have profited from longer-term gains - Simply Wall St

Oct 11, 2024
pulisher
Oct 09, 2024

Antibody Drug Conjugates Industry Report (2024-2032) - GlobeNewswire

Oct 09, 2024
pulisher
Oct 09, 2024

Antibody Drug Conjugates Industry Report (2024-2032) Featuring Profiles the Top 13 PlayersADC Therapeutics, Astellas Pharma, AstraZeneca, Celldex Therapeutics, Roche & More - 24matins.uk

Oct 09, 2024
pulisher
Oct 01, 2024

ADC Therapeutics : Subgroup analyses include patients with double- / triple-hit, advanced stage or transformed DLBCL, DLBCL refractory to first-line therapy, and patients older than 65 (Form 6-K) - Marketscreener.com

Oct 01, 2024
pulisher
Oct 01, 2024

Antibody Drug Conjugates Market Advancements Highlighted by Research 2024-2033 – Outlook, Overview - WhaTech

Oct 01, 2024
pulisher
Oct 01, 2024

ADC Therapeutics SA (NYSE:ADCT) Shares Bought by XTX Topco Ltd - Defense World

Oct 01, 2024
pulisher
Sep 29, 2024

Rhumbline Advisers Purchases Shares of 85,977 ADC Therapeutics SA (NYSE:ADCT) - Defense World

Sep 29, 2024
pulisher
Sep 28, 2024

Adc Therapeutics (ADCT) Price Target Increased by 9.79% to 8.77 - MSN

Sep 28, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: ADC Therapeutics stock faces challenges amid potential growth - Investing.com India

Sep 27, 2024
pulisher
Sep 25, 2024

474,744 Shares in ADC Therapeutics SA (NYSE:ADCT) Purchased by Affinity Asset Advisors LLC - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

Affinity Asset Advisors LLC Makes New Investment in ADC Therapeutics SA (NYSE:ADCT) - Defense World

Sep 25, 2024
pulisher
Sep 24, 2024

205,221 Shares in ADC Therapeutics SA (NYSE:ADCT) Purchased by Bank of New York Mellon Corp - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

205,221 Shares in ADC Therapeutics SA (NYSE:ADCT) Bought by Bank of New York Mellon Corp - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

Adc Therapeutics SA [ADCT] Investment Guide: What You Need to Know - Knox Daily

Sep 23, 2024
pulisher
Sep 22, 2024

Acadian Asset Management LLC Invests $51,000 in ADC Therapeutics SA (NYSE:ADCT) - Defense World

Sep 22, 2024
pulisher
Sep 19, 2024

Buying Buzz: Agree Realty Corp. [ADC] Director RAKOLTA JOHN JR purchases 20,000 shares of the company - Knox Daily

Sep 19, 2024
pulisher
Sep 19, 2024

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue - BioSpace

Sep 19, 2024
pulisher
Sep 19, 2024

ADC Therapeutics SA (NYSE:ADCT) Short Interest Down 8.8% in August - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Short Interest in ADC Therapeutics SA (NYSE:ADCT) Declines By 8.8% - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Addus HomeCare (NASDAQ:ADUS) Reaches New 12-Month High at $136.12 - MarketBeat

Sep 18, 2024
pulisher
Sep 18, 2024

ADC Therapeutics : Cantor Global Healthcare Conference Presentation - Marketscreener.com

Sep 18, 2024
pulisher
Sep 18, 2024

Daily Progress: Agree Realty Corp. (ADC) Drop -0.96, Closing at 75.97 - The Dwinnex

Sep 18, 2024
pulisher
Sep 18, 2024

ADC Therapeutics : Cantor Global Healthcare Conference 2024 Presentation - Marketscreener.com

Sep 18, 2024
pulisher
Sep 16, 2024

Agree Realty (NYSE:ADC) Reaches New 52-Week High at $77.19 - MarketBeat

Sep 16, 2024
pulisher
Sep 16, 2024

Quest Partners LLC Sells 20,070 Shares of Agree Realty Co. (NYSE:ADC) - MarketBeat

Sep 16, 2024
pulisher
Sep 12, 2024

ADC Therapeutics (NYSE:ADCT) Trading 0.5% Higher - MarketBeat

Sep 12, 2024
pulisher
Sep 10, 2024

Adc Therapeutics SA (ADCT) is a good investment, but the stock may be overvalued - US Post News

Sep 10, 2024
pulisher
Sep 10, 2024

Insider’s View: Deciphering Adc Therapeutics SA (ADCT)’s Financial Health Through Ratios - The Dwinnex

Sep 10, 2024
pulisher
Sep 10, 2024

ADCT (Adc Therapeutics SA) may reap gains as insiders became active recently - Knox Daily

Sep 10, 2024
pulisher
Sep 06, 2024

ADC Therapeutics to Present at Upcoming Investor Conferences - Yahoo Finance UK

Sep 06, 2024
pulisher
Sep 02, 2024

Adc Therapeutics SA (ADCT)’s stock performance: a year in review - US Post News

Sep 02, 2024
pulisher
Sep 02, 2024

Are Smart Investors Making the Right Decision? Adc Therapeutics SA (ADCT) - SETE News

Sep 02, 2024

Adc Therapeutics Sa Azioni (ADCT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Capitalizzazione:     |  Volume (24 ore):